Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.

Date publication

février 2018

Journal

Targeted oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Mme POZET Astrid

Tous les auteurs :
Zaanan A, Palle J, Soularue E, Leroy F, Louafi S, Tougeron D, Manfredi S, Artru P, Pozet A, Taieb J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29090377

Résumé

Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. However, there are no safety and efficacy data of trastuzumab with FOLFIRI.

Référence

Target Oncol. 2018 Feb;13(1):107-112